Author:
Hall M,Gourley C,McNeish I,Ledermann J,Gore M,Jayson G,Perren T,Rustin G,Kaye S
Publisher
Springer Science and Business Media LLC
Reference63 articles.
1. Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, Sovak MA, Yi J, Nycum LR (2012) OCEANS: a randomised, double-blinded, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab in patients with platinum sensitive recurrent epithelial ovarian, primary peritoneal or fallopian tube cancer. J Clin Oncol 30: 2039–2045
2. Aghajanian C, Blank SV, Goff BA, Judson PL, Nycum LR, Sovak MA, Yi J, Hussain A (2012) An updated safety analysis of OCEANS, a randomised double-blinded, phase III trial of gemcitabine and carboplatin with bevacizumab or placebo followed by bevacizumab or placebo to disease progression in patients with platinum sensitive recurrent ovarian cancer. J Clin Onc 30 (suppl): ): abstr 5054
3. Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, Giavazzi R, Taraboletti G (1996) The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2 (11): 1843–1849
4. Biagi JJ, Oza AM, Chalchal HI, Grimshaw R, Ellard SL, Lee U, Hirte H, Sederias J, Ivy SP, Eisenhauer EA (2011) A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. Ann Oncol 22 (2): 335–340
5. Bornstein P (1995) Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin 1. J Cell Biol 130 (3): 503–506
Cited by
64 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献